Compare RAIL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | PYXS |
|---|---|---|
| Founded | 1901 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.9M | 124.2M |
| IPO Year | 2005 | 2021 |
| Metric | RAIL | PYXS |
|---|---|---|
| Price | $7.69 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 136.4K | ★ 708.4K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | 3.03 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $500,991,000.00 | $13,858,000.00 |
| Revenue This Year | $6.54 | N/A |
| Revenue Next Year | $30.90 | $7,043.98 |
| P/E Ratio | $6.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.27 | $0.97 |
| 52 Week High | $14.90 | $5.55 |
| Indicator | RAIL | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 44.93 |
| Support Level | $7.58 | $1.23 |
| Resistance Level | $10.18 | $2.27 |
| Average True Range (ATR) | 0.31 | 0.26 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 14.29 | 15.45 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.